EUCTR2018-000873-59-DE进行中（未招募）1 期
Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma - BV-ALLO
niversity of Cologne0 个研究点目标入组 21 人开始时间: 2018年6月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •?- Patients with relapsed/refractory cHL who receive an allogeneic stem cell transplantation
- •?- Histologically proven cHL in the most recent tumor biopsy
- •?- Absolute neutrophil count = 500/mm³
- •?- ECOG =2
- •?- Age = 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?- Presence of nodular lymphocyte-predominant HL (NLPHL)
- •- grey-zone lymphoma
- •?- Progressive disease as last documented response prior to alloSCT
- •?- Any peripheral neuropathy = grade 2
- •?- Any other serious disease or organ dysfunction which might impair protocol Treatment
研究者
相似试验
进行中（未招募）
1 期
Study of the efficiency of brentuximab vedotin in the Hodgkin lymphoma treatment for the patients not cured by standard chemotherapy.EUCTR2013-000734-35-FRYSARC40
进行中（未招募）
1 期
Study of the efficiency of brentuximab vedotin in the Hodgkin lymphoma treatment for the patients not cured by standard chemotherapy.Patients aged from 18 to 70 years with supradiaphragmatic Ann Arbor clinical stage I or II classical Hodgkin lymphoma CD30+, FDG-PET positive score 4 & 5 according to Deauville criteria after 2 courses of ABVD will be included in the trial.MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000734-35-BEYSARC40
已完成
2 期
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDHodgkin LymphomaNCT02298283The Lymphoma Academic Research Organisation40
进行中（未招募）
1 期
Phase I-II study combining Brentuximab Vedotin with second line salvagechemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphomapatients refractory to first line chemotherapy or in first relapse who areeligible for high dose treatment followed by autologous stem celltransplantatioEUCTR2016-001211-21-ESHOVON Foundation55
进行中（未招募）
1 期
Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation.Transplant BRaVE NHCD30 positive diffuse large B-cell lymphomaMedDRA version: 20.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001211-21-BEHOVON Foundation43